Novoron Bioscience

A biotechnology company focused on developing pharmaceutical therapies for nerve regeneration in the central nervous system.

Novoron Bioscience, Inc. was founded in February 2013 as a biotechnology company focused on developing novel therapeutic approaches for the treatment of disorders of the central nervous system (CNS). We are a Delaware C-corp located in San Diego, California. Novoron was founded on the graduate thesis work of our President and CEO, Travis L. Stiles, Ph.D. His published, patent-protected discovery (U.S. Provisional Patent 61/479,210; PCT application filed in April 2012) led to a novel approach to regenerating spinal cord neurons damaged after injury. While spinal cord injury continues to be a major focus of Novoron’s efforts, our pipeline has expanded to include technologies that address multiple CNS disorders. More specifically, in collaboration with academic co-inventors Alban Gaultier, Ph.D. from the University of Virginia, and Dr. Jeffrey Goldberg, M.D., Ph.D. of Stanford University, Novoron is developing further intellectual property for multiple sclerosis and glaucoma.